INTRODUCTION
Colorectal cancer is the second most common cause of cancer related death and the third most common cancer in the United Kingdom.1 2 Around 80% of cases present with spread to the bowel wall. Early diagnosis and recognition of symptoms can now be achieved by screening asymptomatic persons. 3 We now know that between 5 Recently, it has been noted that large genomic rearrangements, that traditionally would not be picked up on genomic sequencing, account formore than 500% ofpathogenic mutations in MLH1/MSH2 in families meeting the Amsterdam criteria.'0 MSH6 mutations are less common; 3.8% of total families, and 14.7% of all families with DNA mismatch repair gene mutations in a German HNPCC cohort,1' had MSH6 gene mutations. They had a later age ofdisease onset and a lower incidence ofCRC, hence almosttwo-thirds offamilies carrying MSH6 mutations would have been missed if the Amsterdam criteria were applied as a 'checklist' to be met prior to molecular testing. A deletion in PMS2 and one nonsense mutation in PMS1 have been described in HNPCC families,'2 however a more recent study by Liu et Revised Bethesda Guidelines for testing colorectal tumours for microsatelllite instability (MSI).
Tumours from individuals should be tested for MSI in the following situations: 1) Colorectal cancer diagnosed in a patient who is less than 50 years of age.
2) Presence ofsynchronous, metachronous colorectal, or other HNPCC associated tumours*, regardless of age.
3) Colorectal cancer with the MSI-Ht histology$ diagnosed in a patient who is less than 60 years of age-. 
